Dublin-listed biopharmaceuticals company Bioglan Pharma has acquired a range of dermatology products from German company Hexal for £16.4m sterling in cash and shares.
Dermatology represents 62% of Bioglan's sales, and the company had said it wanted to expand in the German skin care market.
Bioglan has acquired 12 prescription products, with sales of around £4.7m in the year to July 2000.
* The company is to issue 500,000 new shares worth just over £2.5m to cancel an outstanding loan arrangement with Swedish company Stiftelsen.
